🇺🇸 FDA
Patent

US 9498544

Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents

granted A61KA61K2035/124A61K2039/505

Quick answer

US patent 9498544 (Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents) held by Tissue Regeneration Therapeutics Inc. expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tissue Regeneration Therapeutics Inc.
Grant date
Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2035/124, A61K2039/505, A61K2239/31, A61K35/44